|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008627,
umls-concept:C0010802,
umls-concept:C0021798,
umls-concept:C0023473,
umls-concept:C0023981,
umls-concept:C0162789,
umls-concept:C0205197,
umls-concept:C0871261,
umls-concept:C0936012,
umls-concept:C1552913,
umls-concept:C1704632,
umls-concept:C1704788,
umls-concept:C1706817,
umls-concept:C1707455,
umls-concept:C2603343,
umls-concept:C2911692
|
|
pubmed:issue |
24
|
|
pubmed:dateCreated |
2009-12-7
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
In chronic myeloid leukemia, different methods are available to monitor the response to therapy: chromosome banding analysis (CBA), interphase fluorescence in situ hybridization (I-FISH), and real-time quantitative polymerase chain reaction (RT-Q-PCR). The GIMEMA CML WP (Gruppo Italiano Malattie Ematologiche Adulto Chronic Myeloid Leukemia Working Party) has performed a prospective study to compare CBA and I-FISH for the definition of complete cytogenetic response (CCgR). Samples (n = 664) were evaluated simultaneously by CBA and I-FISH. Of 537 cases in CCgR, the number of positive nuclei by I-FISH was less than 1% in 444 cases (82.7%). Of 451 cases with less than 1% positive nuclei by I-FISH, 444 (98.4%) were classified as CCgR by CBA. The major molecular response rate was significantly greater in cases with I-FISH less than 1% than in those with I-FISH 1% to 5% (66.8% vs 51.6%, P < .001) and in cases with CCgR and I-FISH less than 1% than in cases with CCgR and I-FISH 1% to 5% (66.1% vs 49.4%, P = .004). I-FISH is more sensitive than CBA and can be used to monitor CCgR. With appropriate probes, the cutoff value of I-FISH may be established at 1%. These trials are registered at http://www.clinicaltrials.gov as NCT00514488 and NCT00510926.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1528-0020
|
|
pubmed:author |
pubmed-author:AbruzzeseElisabettaE,
pubmed-author:AlbanoFrancescoF,
pubmed-author:AmabileMarilinaM,
pubmed-author:BaccaraniMicheleM,
pubmed-author:BaldazziCarmenC,
pubmed-author:BernasconiPaoloP,
pubmed-author:CarcassiCarloC,
pubmed-author:CrescenziBarbaraB,
pubmed-author:CuneoAntonioA,
pubmed-author:FugazzaGiuseppinaG,
pubmed-author:GiuglianoEmiliaE,
pubmed-author:GiussaniUrsulaU,
pubmed-author:GozzettiAlessandroA,
pubmed-author:GrimoldiMaria GraziaMG,
pubmed-author:KerimSimonettaS,
pubmed-author:LuattiSimonaS,
pubmed-author:MartinelliGiovanniG,
pubmed-author:MarzocchiGiuliaG,
pubmed-author:NanniMauroM,
pubmed-author:PaneFabrizioF,
pubmed-author:Rege-CambrinGiovannaG,
pubmed-author:RostiGianantonioG,
pubmed-author:StacchiniMonicaM,
pubmed-author:TestoniNicolettaN,
pubmed-author:ZaccariaAlfonsoA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
3
|
|
pubmed:volume |
114
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4939-43
|
|
pubmed:meshHeading |
pubmed-meshheading:19797518-Antineoplastic Agents,
pubmed-meshheading:19797518-Chromosome Banding,
pubmed-meshheading:19797518-Clinical Trials as Topic,
pubmed-meshheading:19797518-Humans,
pubmed-meshheading:19797518-In Situ Hybridization, Fluorescence,
pubmed-meshheading:19797518-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:19797518-Remission Induction,
pubmed-meshheading:19797518-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:19797518-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP.
|
|
pubmed:affiliation |
Department of Hematology-Oncology, L and A Seràgnoli, University of Bologna and S Orsola-Malpighi University Hospital, Bologna, Italy.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
